On 24 January 2013, orphan designation (EU/3/12/1089) was granted by the European Commission to Medical Need Europe AB, Sweden, for choline tetrathiomolybdate for the treatment of Wilson's disease.
The sponsorship was transferred to Wilson Therapeutics AB, Sweden, in July 2014.
The sponsorship was transferred to Alexion Europe S.A.S., France, in February 2019.
The sponsor’s address was updated in November 2019.
|Disease / condition||
Treatment of Wilson's disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;